# US 2010/0168231 A1 · Target enzyme for the treatment of acne

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0168231 A1
- Document ID: US20100168231A1
- Status: Published application
- Kind: A1
- Application number: 12/652,283
- Filed: 2010-01-05
- Published: 2010-07-01
- Earliest claimed: 2007-07-06
- Assignees: Galderma Research & Development
- Inventors: Laurent Lamy; Michel Rivier; Gérard Feraille
- Web page: https://patentgrep.com/patent/US20100168231A1

## CPC

- C12Q 1/32: involving dehydrogenase
- A61K 8/66: Enzymes
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/08: Antiseborrheics
- A61P 17/10: Anti-acne agents
- A61Q 19/008: {Preparations for oily skin}
- G01N 2500/00: Screening for compounds of potential therapeutic value
- G01N 2800/202: Dermatitis
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61Q: SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The use of an enzyme as a research tool for acne, by identifying a compound for the treatment of acne and/or any disorder associated with cutaneous hyperseborrhoea.

## Claims

### Claim 1

An in vitro method for screening and identifying candidate compounds for the preventative and/or curative treatment of a pathology selected from among acne, seborrhoeic dermatitis and cutaneous disorders associated with hyperseborrhoea, comprising determining the capacity of a compound to inhibit the expression or the activity of the human enzyme DHRS9 or the expression of its gene or the activity of at least one of its promoters.

### Claim 2 (depends on 1)

An in vitro method for screening and identifying candidate compounds for the preventative and/or curative treatment of acne, seborrhoeic dermatitis or cutaneous disorders associated with hyperseborrhoea as defined by claim 1, comprising the following steps:
a) preparing at least two biological samples;
b) bringing one of the samples into contact with one or more compounds to be tested;
c) measuring the expression or the activity of the enzyme DHRS9, the expression of its gene or the activity of at least one of the promoters thereof in the biological samples;
d) selecting said compounds for which inhibition of the expression or the activity of the enzyme DHRS9, or inhibition of the expression of its gene or inhibition of the activity of at least one of the promoters thereof in the sample treated in step b) is measured, compared with an untreated sample.

### Claim 3

A pharmaceutical composition comprising an inhibitor of the enzyme DHRS9 in an amount useful for the prevention and/or treatment of acne, seborrhoeic dermatitis or cutaneous disorders associated with hyperseborrhoea.

### Claim 4 (depends on 3)

The pharmaceutical composition as defined by claim 3, wherein said inhibitor is selected from among geranial, neral and carbenoxolone.

### Claim 5 (depends on 3)

A regime or regimen for the treatment of acne or seborrhoeic dermatitis, comprising administering to a subject in need of such treatment, a thus effective amount of the pharmaceutical composition as defined by claim 3.

### Claim 6 (depends on 3)

The pharmaceutical composition as defined by claim 3, formulated for topical application.

### Claim 7 (depends on 3)

The pharmaceutical composition as defined by claim 3, formulated for oral administration.

### Claim 8

A cosmetic composition comprising an inhibitor of the human enzyme DHRS9, in an amount useful for the aesthetic treatment of oily skin.

### Claim 9

An in vitro method for diagnosing or monitoring the evolution of acne, seborrhoeic dermatitis or a cutaneous disorder associated with hyperseborrhoea in a subject, comprising comparing the expression or the activity of the enzyme DHRS9, the expression of its gene or the activity of at least one of the promoters thereof, in a biological sample from a subject, with a biological sample from a control subject.

### Claim 10 (depends on 9)

The method as defined by claim 9, in which the activity of the enzyme is determined by assaying dihydroxytestosterone or 3-alpha-diol in said biological sample.

### Claim 11

A kit for diagnosing acne, comprising the enzyme DHRS9.

### Claim 12

An in vitro method for determining the susceptibility of a subject to developing acne, seborrhoeic dermatitis or a cutaneous disorder associated with hyperseborrhoea, comprising comparing the expression or the activity of the enzyme DHRS9, the expression of its gene or the activity of at least one of the promoters thereof, in a biological sample from a subject, with a biological sample from a control subject.